Drug intelligence / Profile preview

bicisate

Development stage: Approved
Lead developer: Lantheus
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

**Bicisate** is a lipophilic small-molecule ligand used in the diagnostic radiopharmaceutical product **Neurolite**. After reconstitution and chelation with technetium Tc 99m, technetium Tc 99m bicisate passively diffuses across intact cell membranes and the blood-brain barrier; stereospecific intracellular de-esterification then promotes cerebral retention in proportion to regional cerebral blood flow. It is administered intravenously for SPECT imaging as an adjunct to CT or MRI for localization of stroke in patients with an established stroke diagnosis. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9adbcd5-1ac1-42d8-b18a-a76c9204014c))

Brand names: Neurolite
Other names: ethyl cysteinate dimerECDbicisate dihydrochloride

Beyond the preview

Go deeper on bicisate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bicisate.